CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home Item
Suicide by Firearm in the United States: A Collaborative Path for Prevention , homeMarch 6, 2025, 5:30 p.m. (Reception at 5 p.m.) | Marian Betz, M.D., M.P.H. Professor, Departments of Epidemiology and Emergency Medicine, Deputy Director, Injury & Violence Prevention Center, University of Colorado School of Public Health; Member, National Academy of Medicine | Maury Strauss Distinguished Public Lecture
-
Home Item
Thinking the Right Thoughts , homeNathaniel Daw, Ph.D., Professor, Computational and Theoretical Neuroscience, Department of Psychology, Princeton University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
The Emergence of Network Activity Patterns - An Early Window to Autism Spectrum Disorder , homeMarch 14, 2025, 11:00 a.m. | Natalia De Marco Garcia, Ph.D., Associate Professor, Department of Neuroscience, The Brain and Mind Research Institute, Weill Cornell Medical College | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute
-
Home Item
Integration of Sensory, Metabolic and Neural Signals in the Determination of Food Choices and How Dysregulation of These Systems Contributes to Obesity, Diabetes and Cognitive Impairment , homeMarch 21, 2025, 11:00 a.m. | Dana M. Small, Ph.D., Professor, Department of Psychiatry and Psychology, Director, Modern Diet and Physiology Research Center, Yale School of Medicine | Co-Sponsored by the Center for Health Behaviors Research and the Addiction Recovery Research Center, Fralin Biomedical Research Institute
-
Home Item
Social Learning in Borderline Personality Disorder , homeApril 4, 2025, 11:00 a.m. | Sarah Fineberg, M.D., Ph.D., Assistant Professor, Department of Psychiatry, Yale School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
Bringing Precision Medicine to Psychiatry , homeApril 10, 2025, 5:30 p.m. (Reception at 5 p.m.) | Jordan Smoller, M.D., Sc.D., MGH Trustees Endowed Chair in Psychiatric Neuroscience; Professor of Psychiatry, Harvard Medical School; Professor of Epidemiology, T.H. Chan Harvard School of Public Health; Director, Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital | Maury Strauss Distinguished Public Lecture